Brown University

brown.edu

Total trials

278

Active

56

Phase 3

9

Total enrollment

360,633

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 27 of 27 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Hydroxyurea1
Arm I Carboplatin, Paclitaxel, Pembrolizumab1
Arm II Carboplatin, Paclitaxel, Cetuximab1
Arm III Pembrolizumab1
Nivolumab4
Ipilimumab2
Doxazosin2
lenalidomide2
Rucaparib1
Copanlisib1
yttrium-90 radioembolization1
THC-dominant cannabis1
CBD-dominant cannabis1
Cannabis placebo1
Alcohol1
Alcohol placebo1
Ipilumumab1
Trastuzumab deruxtecan1
Tafasitamab1
Polatuzumab vedotin1
Glofitamab1
Obinutuzumab1
Mosunetuzumab1
Dexamethasone1
Regular Human Insulin then Placebo1
Probenecid Oral1
Gemtuzumab Ozogamicin1

Next readouts

  • 2019-03
  • 2023-09-26
  • 2025-05-05
  • 2026-06
  • 2026-06
  • 2026-06-01
  • 2026-08-31
  • 2026-09-01
  • 2026-09-01
  • 2026-12-31

Top conditions

  • Alcohol Drinking12
  • Depression11
  • Alcohol Abuse10
  • HIV9
  • Alcohol Use Disorder8
  • Prostate Cancer7
  • Smoking Cessation7
  • Anxiety7

Frequently asked questions about Brown University

How many clinical trials does Brown University have on ClinicalTrials.gov?
Brown University is listed as the lead sponsor on 278 clinical trials in ClinicalTrials.gov, 56 of which are currently active (recruiting, enrolling, or ongoing).
How many of Brown University's trials are in Phase 3?
9 of Brown University's trials are in Phase 3, spread across 27 active drug programs.
What therapeutic areas does Brown University focus on?
Brown University's most-studied conditions on ClinicalTrials.gov are Alcohol Drinking, Depression, Alcohol Abuse, HIV, Alcohol Use Disorder.
When are Brown University's next clinical trial readouts?
Brown University has 10 upcoming primary-completion readouts tracked here; the soonest is “Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma”, expected around 2019-03.